JENBURPH
Jenburkt Pharmaceuticals financials
- Market cap
- ₹443 Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue down 0.1%, net profit down 24.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 37 | 41 | 36 | 46 +11% | 43 +17% | 45 +9% | 36 −0% |
| EBITDA | 11 | 9 | 11 | 9 | 13 +15% | 7 −16% | 14 +31% | 6 −33% |
| Net profit | 10 | 7 | 9 | 8 | 10 +6% | 6 −9% | 11 +27% | 6 −24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −8.1% 1Y
1Y: ₹1,092.1 on 10 Sept 2025 → ₹1,003.9. High ₹1,275.85 (3 Nov 2025), low ₹955.45 (30 Mar 2026).
Financials, as filed
Revenue grew 9.0% a year over 2 years, FY24 to FY26. Operating margin widened to 25.9%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹142 Cr | ₹152 Cr | ₹169 Cr |
| Operating profit | ₹33 Cr | ₹40 Cr | ₹44 Cr |
| Operating margin | 23.3% | 26.6% | 25.9% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹2 Cr | ₹3 Cr | ₹3 Cr |
| Net profit | ₹26 Cr | ₹32 Cr | ₹35 Cr |
| Net margin | 18.3% | 21.1% | 20.6% |
| Cash from operations | ₹8 Cr | ₹28 Cr | ₹27 Cr |
| Free cash flow | ₹6 Cr | ₹8 Cr | ₹13 Cr |
| ROCE | 26.0% | 27.0% | 27.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Reserves | ₹94 Cr | ₹113 Cr | ₹118 Cr | ₹141 Cr | ₹178 Cr | ₹193 Cr |
| Borrowings | ₹5 Cr | ₹7 Cr | ₹3 Cr | ₹0 Cr | ₹2 Cr | ₹2 Cr |
| Other liabilities | ₹17 Cr | ₹18 Cr | ₹16 Cr | ₹19 Cr | ₹24 Cr | ₹26 Cr |
| Total liabilities | ₹120 Cr | ₹143 Cr | ₹141 Cr | ₹164 Cr | ₹209 Cr | ₹225 Cr |
| Fixed assets | ₹11 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹14 Cr | ₹19 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹52 Cr | ₹46 Cr |
| Investments | ₹7 Cr | ₹8 Cr | ₹11 Cr | ₹17 Cr | ₹27 Cr | ₹27 Cr |
| Other assets | ₹103 Cr | ₹123 Cr | ₹119 Cr | ₹136 Cr | ₹116 Cr | ₹132 Cr |
| Total assets | ₹120 Cr | ₹143 Cr | ₹141 Cr | ₹164 Cr | ₹209 Cr | ₹225 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count grew 6% to 7,103.
- Promoters
- 46.6%
- DIIs
- 0.1%
- Public
- 53.3%
Since Jun 2025
- Public +0.06 pp
- Promoters −0.05 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Over this window the public went from 51.2% to 53.3% — +2.1 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 47.4%, FIIs 1.4%, Public 51.2%.Dec '23: Promoters 47.4%, Public 52.6%.Mar '24: Promoters 47.2%, Public 52.8%.Jun '24: Promoters 46.7%, Public 53.3%.Sep '24: Promoters 46.7%, Public 53.3%.Dec '24: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Mar '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Jun '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Sep '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Dec '25: Promoters 46.6%, DIIs 0.1%, Public 53.2%.Mar '26: Promoters 46.6%, DIIs 0.1%, Public 53.2%.Jun '26: Promoters 46.6%, DIIs 0.1%, Public 53.3%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Optirational Ventures Llp newly disclosed 1.20% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Jenburkt Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ashish Uttam Bhuta | 18.07% | unchanged |
| Bhuta Holdings Private Limited | 13.96% | unchanged |
| Kalindi Hemendra Bhuta | 9.06% | unchanged |
| Nirmala Vinodkumar Daga | 3.30% | unchanged |
| Investor Education And Protection Fund Authority | 2.32% | unchanged |
| Ranjeet Singh Sibia | 1.50% | unchanged |
| Optirational Ventures Llp | 1.20% | newly disclosed |
| Bhavika Ashish Bhuta | 1.17% | unchanged |
| Kunti Ketan Gala | 1.16% | unchanged |
| Rajiv Garg | 1.07% | unchanged |
| Parshva Kumar Daga | 1.05% | unchanged |
| Sushila Paraskumar Daga | 1.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹1004, this stock must grow earnings at 5% every year for 7 years. Our analysis caps realistic growth at ~16%. At that growth it is worth ₹1812 — upside of 80%.
- Growth the price implies
- 4.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 15.6% a year
- net profit, FY24–FY26 · EPS 15.6%
- The gap
- -0.1 pp
- 80% downside if it only repeats history
Learn to analyse Jenburkt Pharmaceuticals Ltd.
Guides on how to read this kind of business and the numbers that matter.